>

Animas Discontinues Sale of Vibe and OneTouch Ping Insulin Pumps

Company Focuses on Newer Technology, Offers Patients Transition Options

WEB Animas, a Johnson & Johnson subsidiary, has announced that it will discontinue the sale of all Animas Vibe and OneTouch Ping insulin pumps in the United States and Canada. The decision was made after careful consideration and is part of the company's ongoing efforts to focus on developing and delivering innovative diabetes management solutions.

Patient Transition Options

WEB Animas is committed to supporting its patients during this transition. Patients who currently use an Animas Vibe or OneTouch Ping pump will have the option to switch to a Medtronic insulin pump or to continue using their current pump until the end of its useful life.

WEB Animas will provide comprehensive support to patients making this transition, including working with their healthcare providers to select the best pump for their individual needs and providing training on how to use the new pump.

Focus on Innovation

The decision to discontinue the sale of the Animas Vibe and OneTouch Ping pumps is part of WEB Animas's ongoing commitment to innovation. The company is investing heavily in the development of new products and technologies that will help people with diabetes manage their condition more effectively.

WEB Animas is confident that this decision will allow the company to focus its resources on developing and delivering the next generation of diabetes management solutions.